Mostrar el registro sencillo del ítem
Autor | Vergara, Tânia R. C. | |
Autor | Samer, Sadia | |
Autor | Oliveira, Joanna R. Santos | |
Autor | Giron, Leila B. | |
Autor | Arif, Muhammad Shoaib | |
Autor | Freitas, Maria Luciana Silva | |
Autor | Cherman, Lia A. | |
Autor | Treitsman, Mauro S. | |
Autor | Chebabo, Alberto | |
Autor | Sucupira, Maria Cecilia A. | |
Autor | Cruz, Alda M. da | |
Autor | Diaz, Ricardo Sobhie | |
Fecha de acceso | 2018-03-01T13:12:45Z | |
Fecha de disponibilización | 2018-03-01T13:12:45Z | |
Fecha de publicación | 2017 | |
Referencia | VERGARA, Tânia R. C. et al. Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety. EBiomedicine, v.23, p.59-67. 2017. | pt_BR |
ISSN | 2352-3964 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/25013 | |
Idioma | eng | pt_BR |
Editor | Elsevier | pt_BR |
Derechos de autor | open access | pt_BR |
Palabras clave en Portugués | HIV | pt_BR |
Palabras clave en Portugués | Talidomida | pt_BR |
Palabras clave en Portugués | Inflamação | pt_BR |
Palabras clave en Portugués | Agente de reversão de latência | pt_BR |
Palabras clave en Portugués | Ativação de células T | pt_BR |
Título | Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety | pt_BR |
Tipo del documento | Article | pt_BR |
DOI | 10.1016/j.ebiom.2017.08.007 | |
Resumen en Inglés | Trial Design: Open-label, randomised, controlled, pilot proof-of-concept clinical trial. Methods: Participants: Antiretroviral naïve adult males with CD4 count ≥350 cells/mm3. Interventions: Patients were randomised to receive thalidomide 200 mg QD for 3 weeks (Thalidomide group) or not (Control group) and followed for 48 weeks. Objective: We hypothesized that short-term Thalidomide use would reduce HIV related inflammation and HIV replication among antiretroviral naïve HIV infected individuals. Outcome: Viral loads, CD4/CD8 counts, ultra-sensitive C-reactive protein (US-CRP), cell activation markers, and plasma lipopolysaccharide (LPS) were analyzed. Randomisation: Unrestricted randomisation. Blinding: No blinding was used. Results: Numbers randomised: Thirty recruited individuals were randomised to Thalidomide (16 patients) or Control (14 patients) groups. Recruitment: Patients were recruited from April 2011 to January 2013. Outcome: Viral loads remained stable in both groups. During thalidomide treatment, a decrease in CD4/CD8 ratio (p=0.04), a decrease in CD4 count (p=0.04), an increase in cell activation calculated by the percentage of CD38 +/HLA-DR+ CD8 cells (p b 0.05) and an increase in US-CRP (p b 0.01) were observed in the Thalidomide group, with all parameters returning to baseline levels after thalidomide interruption.We confirmed that thalidomide increased HIV replication in vitro of 6 of 7 samples from long-term antiretroviral suppressed individuals. Harms: No class 3/4 adverse events occurred. Conclusions: Short-termuse of thalidomide led to an intense transient increase in T cell activation and inflammation, with a decrease in the CD4+ cell count without changes to the CD8+ cell count. We confirmed that thalidomide acts in vitro as a latency reversal agent and speculate that the in vivo results obtained were due to an increase in HIV replication. | pt_BR |
Afiliación | Universidade Federal de São Paulo. Laboratório de Retrovirologia. São Paulo, SP, Brasil / Oncohiv. Rio de Janeiro, RJ, Brasil. | pt_BR |
Afiliación | Universidade Federal de São Paulo. Laboratório de Retrovirologia. São Paulo, SP, Brasil. | pt_BR |
Afiliación | Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro. Rio de Janeiro, Brasil. | pt_BR |
Afiliación | Universidade Federal de São Paulo. Laboratório de Retrovirologia. São Paulo, SP, Brasil. | pt_BR |
Afiliación | Universidade Federal de São Paulo. Laboratório de Retrovirologia. São Paulo, SP, Brasil. | pt_BR |
Afiliación | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Interdisciplinar de Pesquisas Médicas. Rio de Janeiro, RJ. Brasil. | pt_BR |
Afiliación | Secretaria Municipal de Saúde Antônio Ribeiro Neto. Rio de Janeiro, RJ, Brasil | pt_BR |
Afiliación | Oncohiv. Rio de Janeiro, RJ, Brasil. | pt_BR |
Afiliación | Oncohiv. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brasil. | pt_BR |
Afiliación | Universidade Federal de São Paulo. Laboratório de Retrovirologia. São Paulo, SP, Brasil. | pt_BR |
Afiliación | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Interdisciplinar de Pesquisas Médicas. Rio de Janeiro, RJ. Brasil. | pt_BR |
Afiliación | Universidade Federal de São Paulo. Laboratório de Retrovirologia. São Paulo, SP, Brasil. | pt_BR |
Palavras clave en Inglês | Thalidomide | pt_BR |
Palavras clave en Inglês | T cell activation | pt_BR |
Palavras clave en Inglês | Inflammation | pt_BR |
Palavras clave en Inglês | Latency reversal agent | pt_BR |
Palavras clave en Inglês | HIV | pt_BR |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
IOC - Artigos de Periódicos [12500]